Acinetobacter Pneumonia Therapeutics Market
According to Intent Market Research, the Acinetobacter Pneumonia Therapeutics Market is expected to grow from USD 421.6 million in 2023 at a CAGR of 7.8% to touch USD 715.3 million by 2030. The Acinetobacter Pneumonia Therapeutics Market is dominated by key players such as, AstraZeneca, AbbVie Inc., GlaxoSmithKline plc, Eli Lilly and Company, and Novartis International AG.